BJH - volume 3, issue 2, june 2012
M.L. Zandvliet PhD
On the 22nd of March 2011, M.L. Zandvliet defended his thesis entitled ‘Adoptive immunotherapy for viral infections after allogeneic stem cell transplantation’ at the University of Leiden, The Netherlands. The research described in this thesis was supervised by professor H.-J. Guchelaar, PharmD, professor J.H.F. Falkenburg, MD, and Dr. P. Meij, PhD. The most important findings of his thesis research are summarised in this report.
(BELG J HEMATOL 2012;3:68–70)
Read moreBJH - volume 3, issue 1, march 2012
A. Van Driessche PhD, MSc, V.F.I. Van Tendeloo PhD, MSc, Z.N. Berneman MD, PhD
Dendritic cell (DC)-based vaccination holds promise as an adjuvant immunotherapy for many cancers. The Wilms’ tumour (WT1) protein is overexpressed in most types of leukaemia and in many solid tumours. Therefore, WT1 could be regarded as a broadly applicable tumour-associated antigen in DC-based immunotherapy. In this thesis, we pursued the aim to enhance antileukemic immune response by the activation of WT1-specific T cells. We developed – from bench to bedside – a therapeutic vaccine of DC loaded with WT1 for patients with acute myeloid leukaemia (AML).
(BELG J HEMATOL 2012;3:24–6)
Read more
Top
